Skip to main content
    F

    FibroBiologics, Inc. Common Stock (FBLG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.90
    -0.02 (-2.56%)

    Market Cap: $6.57M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    FibroBiologics, Inc. Common Stock (FBLG) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to FibroBiologics, Inc. Common Stock are GT Biopharma (GTBP), Theriva Biologics (TOVX) and GRI Bio (GRI). By market cap, FibroBiologics, Inc. Common Stock ranks 9th of the 13 companies on this page; Pluri (PLUR) is the largest at $15.09M.

    Peer Comparison

    FBLG's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    FibroBiologics, Inc. Common Stock (FBLG)$6.57MN/AN/A0.0%N/A0.0%0.00%
    GT Biopharma Inc (GTBP)$7.67MN/AN/A0.0%N/A0.0%0.00%
    Theriva Biologics Inc. (TOVX)$6.61MN/A21.5x0.0%-52.3%0.0%0.00%
    GRI Bio Inc. (GRI)$3.72MN/AN/A0.0%N/A0.0%0.00%
    In8bio Inc (INAB)$8.86MN/AN/A0.0%N/A0.0%0.00%
    Can Fite Biopharma Ltd ADR (CANF)$4.30MN/A14.3x0.0%-156.8%0.0%0.00%
    Longeveron LLC (LGVN)$8.40MN/A5.9x0.0%N/A-9.2%0.00%
    PharmaCyte Biotech Inc (PMCB)$3.77MN/AN/A0.0%N/A0.0%0.00%
    Biocardia Inc (BCDA)$12.58MN/AN/A0.0%N/A-100.0%0.00%
    Pluri Inc. (PLUR)$15.09MN/A8.7x0.0%-650.8%-15.8%0.00%
    Moleculin Biotech Inc (MBRX)$8.02MN/AN/A0.0%N/A0.0%0.00%
    Biovie Inc (BIVI)$12.12MN/AN/A0.0%N/A0.0%0.00%
    Creative Medical Technology Holdings Inc (CELZ)$4.01MN/AN/A0.0%N/A0.0%0.00%
    Peer median$7.84MN/A11.5x0.0%-156.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to FibroBiologics, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    GT Biopharma Inc (GTBP)
    GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its...
    GTBP competitors
    Theriva Biologics Inc. (TOVX)
    Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need.
    TOVX competitors
    GRI Bio Inc. (GRI)
    GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology.
    GRI competitors
    In8bio Inc (INAB)
    IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers...
    INAB competitors
    Can Fite Biopharma Ltd ADR (CANF)
    Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of cancer...
    Longeveron LLC (LGVN)
    Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions.
    LGVN competitors
    PharmaCyte Biotech Inc (PMCB)
    PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United...
    PMCB competitors
    Biocardia Inc (BCDA)
    BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease.
    BCDA competitors
    Pluri Inc. (PLUR)
    Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy...
    PLUR competitors
    Moleculin Biotech Inc (MBRX)
    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant...
    MBRX competitors
    Biovie Inc (BIVI)
    BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States.
    BIVI competitors
    Creative Medical Technology Holdings Inc (CELZ)
    Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics...
    CELZ competitors

    Frequently Asked Questions About FBLG

    Who are FibroBiologics, Inc. Common Stock's main competitors?

    The companies most similar to FibroBiologics, Inc. Common Stock include GT Biopharma (GTBP), Theriva Biologics (TOVX), GRI Bio (GRI), In8bio (INAB) and Can Fite Biopharma Ltd ADR (CANF), listed from the closest match.

    Who is FibroBiologics, Inc. Common Stock's biggest competitor?

    Pluri (PLUR) is the largest of the similar companies at $15.09M; GT Biopharma (GTBP) is the closest match by business profile, size, sector and industry.

    How does FBLG stock compare with its competitors?

    FBLG's net margin is 0.0% against a peer median of 0.0%.

    Which of FibroBiologics, Inc. Common Stock's competitors pays a higher dividend?

    FibroBiologics, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is FibroBiologics, Inc. Common Stock bigger than its competitors?

    No. FibroBiologics, Inc. Common Stock is 9th by market cap among the 13 companies on this page; the largest is Pluri (PLUR) at $15.09M.